ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1375

Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?

Charlotte Baert1, Charlene Mouafo Toukam2, Tatiana Sokolova3, Maria S. Stoenoiu4, Patrick Durez5, Laurent Meric De Bellefon2 and Adrien Nzeusseu Toukap6, 1Rheumatology department, St-Luc university hospitals, Brussels, Belgium, 2Rheumatology department; St-Luc University Hospitals, Brussels, Belgium, 3Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 41Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, 5Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 61Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium

Meeting: ACR Convergence 2020

Keywords: , , ,

Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in Ankylosing Spondylitis and nonradiographic AxSpA patients treated without biologics (BIOL) occurs infrequently (Ref 1, 2). Few are known about remission rate (RR) in daily clinical practice. Our aim was to assess the remission rate (RR) in AxSpA patients in real life, and to compare the RR in AxSpA patients on NonSteroidal Anti-Inflammatory Drugs (NSAIDs) to RR for those on BIOL (anti-TNFα or IL-17A blockers).

Methods: This cross-sectional study reviewed clinical data from a single center (St-Luc university hospitals, UCLouvain, Brussels) from 01/2013 to 03/2019. Last visit available for clinical assessment was evaluated. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score using the C-reactive protein (ASDAS-CRP). Remission was defined as BASDAI < 4 and ASDAS-CRP < 1.3.

Results: Data from 551 AxSpA patients were reviewed. 353 were men (64.3%). In the entire cohort, 478 BASDAI and 316 ASDAS-CRP were recorded. The RR according to the BASDAI was 46.7% (n = 223), and 17.4% for the ASDAS-CRP (n = 55). To look for the treatment-related RR, we stratified by the treatment (NSAIDs vs BIOL). We had 285 patients on NSAIDs (177 men, 62.5%) and 266 on BIOL (176 men, 66%). 245 BASDAI were available for NSAIDs and 233 for BIOL. 110 patients on NSAIDs (44.9%) and 113 on BIOL (48.5%) were in remission for BASDAI. Regarding ASDAS-CRP (see table below), data from 172 patients on NSAIDs and 144 on BIOL were available. Out of them, 27 (15.7%) and 28 (19.4%) were in remission for NSAIDs and BIOL respectively. Chi-square test: p = 0.853.

Table: Distribution of ASDAS-CRP values in both groups (n = 316).

ASDAS-CRP

< 1.3

ASDAS-CRP

≥ 1.3 < 2.1

ASDAS-CRP

≥ 2.1 ≤ 3.5

ASDAS-CRP

> 3.5

NSAIDs (n = 172)

N = 27 (15.7%)

N = 41 (23.8%)

N = 70 (40.7%)

N = 34 (19.8%)

BIOL (n = 144)

N = 28 (19.4%)

N = 30 (20.8%)

N = 57 (39.6%)

N = 29 (20.1%)

Conclusion: In the real life, RR in AxSpA is higher on BIOL even if compared to NSAIDs the difference is not statistically significant. However, many patients on NSAIDs achieve the remission.

References

  • Deodhar A. et al. Arthritis Rheumatol 2019 Jul; 71(7):1101-1111.
  • Sieper J. et al. Rheumatology (Oxford) 2016 Nov; 55(11): 1946-1953.
Disclosure: C. Baert, None; C. Mouafo Toukam, None; T. Sokolova, None; M. Stoenoiu, UCB, 2, 8, Roche, 2, Abbvie, 2, MSD, 9, Sanofi, 9, Cellgen, 9; P. Durez, None; L. Meric De Bellefon, None; A. Nzeusseu Toukap, AbbVie, 1, 2, Eli Lilly, 1, 2, Janssen, 1, 2, UCB, 1, 2, Novartis, 1, Celgene Corporation, 1, Pfizer, 1.

To cite this abstract in AMA style:

Baert C, Mouafo Toukam C, Sokolova T, Stoenoiu M, Durez P, Meric De Bellefon L, Nzeusseu Toukap A. Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/remission-in-axial-spondyloarthritis-is-there-a-difference-between-nsaids-and-biologics-in-the-real-life/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/remission-in-axial-spondyloarthritis-is-there-a-difference-between-nsaids-and-biologics-in-the-real-life/